Application of gastrodin to preparing medicaments for preventing and treating Alzheimer's disease

Abstract

The invention discloses an application of gastrodin to preparing medicaments for preventing and treating Alzheimer's disease. Alzheimer's disease (AD) is a neurodegenerative disease, and pathological characteristics comprise neuro fibrillary tangles formed in cells, hyperplasia of reactive microglia and glial cell, and the like, wherein the extracellular deposition of amyloid A beta is the main pathogenetic reason of AD. An AD small mouse taking a gastrodin-containing fodder is substantially improved in spatial-memory learning ability, substantially reduced in A beta level in brain and serum, and substantially reduced in amyloid plaques and microglia in brain tissue, and thus it is indicated that gastrodin is capable of preventing A beta deposition and decreasing active components causing AD mouse brain gastrodin.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to the application of gastrodin in the preparation of medicines for preventing and treating Alzheimer's disease. Background technique [0002] Dementia is a combination of adverse conditions that affect memory, thinking, behavior and the ability to perform daily tasks. According to the 2009 World Alzheimer's Disease Report, by 2050, 115 million people worldwide will be affected by this disease. (World Alzheimer Report 2009 Martin Prince, Jim Jackson et al. 2009). The pathological hallmark of AD is the deposition of amyloid neuritis plaque protein (Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297: 353–356), the formation of nerve fibers Tangling, simultaneous reactive microglia and astrogliosis, a cascade of chronically activated microglia releasing chemokines and impaired cytokine...

AI Technical Summary

Problems solved by technology

[0004] At present, these drugs still have great deficiencies: (1) there is no ideal first-line drug corresponding to the treatment or reversal of the course of the disease, such as acetylcholine inhibitors (AChE), which can only alleviate the cognitive impairment of early patients and moderately improve symptoms, but cannot stop disease progression

(2) Some drugs have serious side effects. For example, estrogen therapy can reduce the risk of AD in women, but it is only suitable for postmenopausal women, and can increase the incidence of breast cancer, endometrial cancer, and ovarian cancer.

(3) New drug research and development, chemical synthesis is very difficult

Based on the hypothesis of amyloid protein, Aβ40, Aβ42 and inflammatory factors are the targets, systematic studies from cell molecules to organs and whole animal levels are lacking, and there is a lack of comprehensive pharmacological mechanism description for the prevention and treatment of Alzheimer's disease

Images